1: Ricci C, Scappini B, Divoky V, Gatto S, Onida F, Verstovsek S, Kantarjian HM, Beran M. Related Articles, Links
Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
Cancer Res. 2002 Nov 1;62(21):5995-8.
PMID: 12414617 [PubMed - indexed for MEDLINE]
2: Barthe C, Gharbi MJ, Lagarde V, Chollet C, Cony-Makhoul P, Reiffers J, Goldman JM, Melo JV, Mahon FX. Related Articles, Links
Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.
Br J Haematol. 2002 Oct;119(1):109-11.
PMID: 12358910 [PubMed - indexed for MEDLINE]
3: Corbin AS, Buchdunger E, Pascal F, Druker BJ. Related Articles, Links
Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.
J Biol Chem. 2002 Aug 30;277(35):32214-9.
PMID: 12077114 [PubMed - indexed for MEDLINE]
4: Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP. Related Articles, Links
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.
Blood. 2002 May 1;99(9):3472-5.
PMID: 11964322 [PubMed - indexed for MEDLINE]
5: Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG, Koeffler HP. Related Articles, Links
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.
Blood. 2002 Mar 1;99(5):1860-2.
PMID: 11861307 [PubMed - indexed for MEDLINE]
Time used: 63 miliseconds.

Webpage designed by Dr. Xueliang Fang, last updated on 3/10/2005